Qms Medical Allied Services Limited · NSE:QMSMEDI
Qms Medical Allied Services — Q4 FY24 Earnings Presentation
31 slides from Qms Medical Allied Services's earnings presentation, May 24, 2024
Slide 1: NSE Regulation 30 announcement cover letter
To, National Stock Exchange of India Ltd. Plaza, C 1, Block G, Bandra - Kurla Complex, Bandra (E), Mumbai – 400 051, Maharashtra, India. Company Symbol: QMSMEDI ISIN: INE0FMW01018 Ref: QMS MEDICAL ALLIED SERVICES LIMITED Sub: Announcement under Regulation 30 of Securities and Exchange Board of India
Slide 2: Q4 FY24 Investor Presentation
QMS Medical Allied Services Limited Q4 FY24 INVESTOR PRESENTATION
Slide 3: Disclaimer
Disclaimer This presentation or any other documentation or information (or any part thereof) delivered or supplied should not be deemed to constitute prospectus or placement memorandum or an offer to acquire any securities. N o representation or warranty, express or implied is made as to, and no reli
Slide 4: Q4 FY24 Financial & Operational Highlights
Q4 FY24 Financial & Operational Highlights 3
Slide 5: Q4 FY24 Financial Highlights
Q4 FY24 Financial Highlights Total Income EBITDA EBITDA % Net Profit Net Profit % 12.54 4.97 32.40 10.61 4.57 31.56 4.06 1.57 1.54 3.35 Q4 FY23 Q4 FY24 Q4 FY23 Q4 FY24 Q4 FY23 Q4 FY24 All Figures In ₹ Cr & Margin In % qmsmas.com 4 qmsmas.com
Slide 6: Q4 & H2 FY24 Financial Highlights
Q4 & H2 FY24 Financial Highlights In ₹ Cr Particulars Q4 FY24 Q4 FY23 Y-O-Y % H2 FY24 H2 FY23 Y-O-Y % Net Sales 32.29 31.37 67.53 52.07 Other Income 0.11 0.19 0.26 0.38 Total Income 32.40 31.56 2.66% 67.78 52.46 16.99% Expenses Raw Material costs 21.20 23.39 45.30 37.69 Employee Benefit Expenses 1.6
Slide 7: QMS MAS's Acquisition Of Saarathi Healthcare
QMS MAS's Acquisition Of Saarathi Healthcare o While QMS MAS specializes in the patient screening programs, Saarathi has been a pioneer in the next phase, which is disease management and patient support. o The acquisition of Saarathi Healthcare allows QMS MAS to provide a comprehensive portfolio of
Slide 8: Two Lakhs Patients Empowered by Diagnostic Screenings
Two Lakhs Patients Empowered by Diagnostic Screenings Conducted over 25,000 unique patient service programs. • Partnered with top pharmaceutical companies to expand reach and efficacy. • Benefited 2,00,000 patients with advanced diagnostic screenings including: o Diabetic Retinopathy Testing o Spiro
Slide 9: Company Overview
Company Overview 8
Slide 10: Introducing QMS MAS Limited - Your Partner In Healthcare Services
Introducing QMS MAS Limited - Your Partner In Healthcare Services Founded and led by Primary Sales Modules: Mr. Mahesh Makhija, a Provision of Customized Business Professional with A publicly listed company Scientific Solutions to over 33 years of experience that is showing consistent assist the top
Slide 11: Unwavering Progress: Growing from Strength To Strength
Unwavering Progress: Growing from Strength To Strength 5 900 + 130 + Business Verticals SKUs Customers 02 04 06 01 03 05 150 + FY 23-24 Asset Light Employees Revenue - ₹ 122.58 Cr. Business Model EBITDA - ₹ 18.80 Cr. PAT - ₹ 9.00 Cr. qmsmas.com 10 qmsmas.com
Slide 12: Diversified Portfolio: Exploring Our Business Verticals
Diversified Portfolio: Exploring Our Business Verticals Business to Business (B2B) Utility Inputs Patient Service Programs OPTHALMIC Seeing beyond Educamedics Point Of Care B2C Medical Devices And Equipment qmsmas.com 11 qmsmas.com
Slide 13: Healthcare Expansion: Nationwide Reach & Expertise
Healthcare Expansion: Nationwide Reach & Expertise 300+ Addressable 110 trained and certified Locations across the span DMLT’s, each capable of of the country covering a 35 km radius 600+ Dietitian Network Leading USFDA Approved capable of providing Devices are used at all site customized comfort an
Slide 14: The Unique Patient Service Program Conducted By QMS MAS
The Unique Patient Service Program Conducted By QMS MAS Patient Service Program (PSPs) are a first of its kind initiative by QMS Medical Allied Services to empower healthcare practitioners with data that can help improve therapy outcomes for their patients. QMS MAS organizes preventive screening cam
Slide 15: Lupin Limited's DITI Program In Partnership With QMS MAS
Lupin Limited's DITI Program In Partnership With QMS MAS ▪ The DITI program is the Humrahi program which currently helps over 10,000 patients manage their diabetes through lifestyle management. ▪ The program is under the auspice of Lupin ltd but managed by QMS MAS LTD. qmsmas.com 14 qmsmas.com
Slide 16: QMS MAS's Unique Competitive Edge
QMS MAS's Unique Competitive Edge o Proven track record of doing business with the top 50 pharmaceutical companies in India for over 20 years. o Experienced and highly qualified marketing team that has deep relationships and repeated success amongst our clientele. o Well managed and organized back-o
Slide 17: Key Management
Key Management Mr. Mahesh Makhija Promoter, Chairperson & Managing Director Age: 53 years He has around 28 years of rich experience in the field of medical and healthcare devices. He is currently responsible for formulating business strategies and oversight of day to day functioning of the Company.
Slide 18: Industry Overview
Industry Overview 17
Slide 19: Pharma Market: A Comprehensive Industry Overview
Pharma Market: A Comprehensive Industry Overview Retail Sector Hospital Sector Dispensing Sector Unaudited Sector Retail Sector (In ₹ Billions) Hospital Sector (In ₹ Billions) Dispensing Doctors (In ₹ Billions) Unaudited Sector (In ₹ Billions) 187.8 1773 173.8 1634 136.4 298.2 159.6 125.7 274.9 1501
Slide 20: Capitalizing On Industry Marketing Budgets: QMS MAS's Growth Path
Capitalizing On Industry Marketing Budgets: QMS MAS's Growth Path The annual marketing spends allocated by the industry represent a pivotal market opportunity for QMS MAS, offering a strategic pathway for expanding its reach and influence within the market. Approximate advertising / promotional spen
Slide 21: Key Drivers Elevating Patient Service Programs (PSP)
Key Drivers Elevating Patient Service Programs (PSP) Start Probability Leveraging Event Title Year Value Tactic Regulatory Changes In Traditional Pharmaceutical 2024 95% Marketing Efforts to Doctors Increase in specific diagnostics / PSP, PAP and awareness of programs Recent and Future Product Launc
Slide 22: The Way Forward
The Way Forward 21
Slide 23: Anticipated 3-Year Growth Across Key Segments
Anticipated 3-Year Growth Across Key Segments The Humrahi program Patient Service Programs Point Of Care(POC) o White-labeling for further o Expansion of Workforce o Expansion of Product and pharmaceutical companies o Expansion of Service Areas Renewable Offerings o B2C Expansion o Expansion of Clie
Slide 24: Financial Overview
Financial Overview 23
Slide 25: Key Financial Highlights
Key Financial Highlights Total Income EBITDA EBITDA Margin Net Profit Net Profit Margin 18.80 147.74 18.06 10.69 122.58 9.00 15.34 104.78 12.07 12.22 6.38 7.34 11.51 7.23 6.09 FY22 FY23 FY24 FY22 FY23 FY24 FY22 FY23 FY24 Amount In ₹ Cr & Margin in % qmsmas.com 24 qmsmas.com
Slide 26: Key Financial Highlights
Key Financial Highlights In % In Times In ₹ ROE Debt To Equity Book Value 1.03 43.99 34.44 39.44 0.44 17.39 11.47 0.36 9.06 FY22 FY23 FY24 FY22 FY23 FY24 FY22 FY23 FY24 ROCE In % Interest Coverage In Times Earnings Per Share In ₹ 26.81 7.10 6.93 4.81 4.91 5.04 13.59 3.90 11.46 FY22 FY23 FY24 FY22 FY
Slide 27: Profit & Loss Statement
Profit & Loss Statement In ₹ Cr Particulars FY24 FY23 FY22 Revenues 122.13 104.04 146.32 Other Income 0.46 0.74 1.42 Total Revenue 122.58 104.78 147.74 Raw Material costs 79.92 77.88 110.31 Employee costs 5.50 3.72 4.67 Other expenses 18.36 11.11 14.71 Total Expenditure 103.78 92.72 129.69 EBITDA 18
Slide 28: Balance Sheet
Balance Sheet In ₹ Cr Equities & Liabilities FY24 FY23 FY22 Assets FY24 FY23 FY22 Equity 17.85 17.85 3.76 Non Current Assets Reserves 60.66 52.55 27.27 Fixed assets 25.63 26.52 7.97 Net Worth 78.51 70.40 31.03 Non-current investments 0.00 0.00 0.00 Non-current Liabilities Deferred Tax Assets 0.00 0.
Slide 29: Revenue From Top 10 Customers
Revenue From Top 10 Customers FY22 SALES FY23 SALES FY24 SALES 14% 11% 12% 146.32 Cr 104.04 Cr 122.13 Cr 86% 88% 89% Top 10 Others qmsmas.com 28 qmsmas.com
Slide 30: Stock Data
Stock Data NSE Code: QMSMEDI As on 24-05-2024 Share Holding Pattern As on 31-03-2024 Share Price (₹) 106.35 26.34% Market Capitalization (₹) Cr 189.83 Promoters No. of Share Outstanding 1,78,50,000 NII Face Value (₹) 10.00 73.67% 52 week High-Low (₹) 189.00 / 102.55 Share Performance From 11th Octob
Slide 31: Thank You
Thank You QMS Medical Allied Services Limited Kirin Advisors Private Limited 1A-B/2A-B, Navkala Bharti Building, 713-B, Lodha Supremus II, Wagle Estate, Plot No.16, Prabhat Colony, Road No.3, Thane West – 400 604. Santacruz East, Mumbai, (India) 400055. Phone: 022 4100 2455 Phone: 022 6288 1111 Emai
QMS Medical Allied Services — Q4 FY24 Earnings Presentation on 6ix